Table 2.

Parameters of monocyte function and distribution in survivors vs. non-survivors on day 0.

Parameter	Survivor	Non-survivor	P-value
F7 (–) [%]	45.4 ± 5.7	26.9 ± 5.7	0.03
MAN-1 (–) [%]	22.0 ± 7.6	15.8 ± 2.7	0.45
CD163 (–) [%]	45.1 ± 7.7	42.5 ± 8.0	0.82
CX3CR1 (–) [%]	50.7 ± 8.4	52.1 ± 7.2	0.91
CD69 (–) [%]	0.3 ± 0.1	0.6 ± 0.2	0.06
CD86 (–) [%]	0.4 ± 0.1	1.1 ± 0.6	0.19
HLA (–) [MFI]	2058 ± 317	2289 ± 371	0.64
F7 (+) [%]	52.8 ± 7.6	33.4 ± 6.1	0.06
MAN-1 (+) [%]	39.3 ± 7.4	26.9 ± 6.1	0.21
CD163 (+) [%]	43.3 ± 7.8	35.5 ± 6.5	0.45
CX3CR1 (+) [%]	37.9 ± 7.5	41.3 ± 7.1	0.75
CD69 (+) [%]	1.0 ± 0.4	0.4 ± 0.1	0.20
CD86 (+) [%]	0.9 ± 0.3	0.9 ± 0.3	0.98
Total monocytes/ml	231,152 ± 42,618	352,547 ± 103,541	0.29
Classical monocytes/ml	151,932 ± 30,503	281,890 ± 85,492	0.15
Intermediate monocytes/ml	27,345 ± 6,394	119,940 ± 45,829	0.05
Non-classical monocytes/ml	13,761 ± 3,994	18,971 ± 5,620	0.45
Classical monocytes [%]	65.6 ± 3.9	56.2 ± 5.8	0.19
Intermediate monocytes [%]	14.7 ± 2.8	20.6 ± 3.7	0.22
Non-classical Monocytes [%]	5.9 ± 1.2	4.9 ± 0.9	0.47

Baseline monocyte activation is indicated by (–), monocyte stimulability is indicated by (+). Survivors were defined as patients weaned off VA-ECMO and discharged from the intensive care ward. Monocyte activation was defined as described in the Materials and Methods section. p-values were calculated by an unpaired t-test. Significant p-values are written in bold. Data are presented as mean ± SEM. HLA, human leukocyte antigen; MFI, mean fluorescence intensity.